Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Equinox Sciences
Newport Beach, California, United Statesequinoxus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vorolanib, a small-molecule tyrosine kinase inhibitor targeting PDGFR and VEGFR, has demonstrated positive Phase 1 clinical results for wet AMD (EYP-1901, via EyePoint's delivery system). Approved in China for renal cell carcinoma; multiple ophthalmic trials ongoing/planned.
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
EyePoint Pharmaceuticals (exclusive global ophthalmic license, outside China)Betta Pharmaceuticals (China regional rights)
Beyond the preview
Go deeper on Equinox Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equinox Sciences.